Werewolf Therapeutics (NASDAQ:HOWL) Major Shareholder Bioventures 2014 L.P. Mpm Sells 47,950 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) major shareholder Bioventures 2014 L.P. Mpm sold 47,950 shares of Werewolf Therapeutics stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $1.22, for a total value of $58,499.00. Following the sale, the insider directly owned 5,959,172 shares of the company’s stock, valued at approximately $7,270,189.84. This trade represents a 0.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Thursday, November 6th, Bioventures 2014 L.P. Mpm sold 54,452 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.21, for a total value of $65,886.92.
• On Tuesday, November 4th, Bioventures 2014 L.P. Mpm sold 140,488 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total value of $171,395.36.
• On Monday, November 3rd, Bioventures 2014 L.P. Mpm sold 94,063 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.29, for a total value of $121,341.27.
• On Friday, October 31st, Bioventures 2014 L.P. Mpm sold 114,044 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.28, for a total transaction of $145,976.32.
• On Thursday, October 30th, Bioventures 2014 L.P. Mpm sold 86,936 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.43, for a total transaction of $124,318.48.
• On Wednesday, October 29th, Bioventures 2014 L.P. Mpm sold 134,240 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.55, for a total transaction of $208,072.00.
• On Tuesday, October 28th, Bioventures 2014 L.P. Mpm sold 69,068 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.64, for a total transaction of $113,271.52.
• On Monday, October 27th, Bioventures 2014 L.P. Mpm sold 72,709 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.72, for a total transaction of $125,059.48.

Werewolf Therapeutics Trading Down 6.3%

NASDAQ HOWL traded down $0.08 during trading on Friday, hitting $1.13. 118,929 shares of the company’s stock traded hands, compared to its average volume of 498,261. The stock has a fifty day moving average of $1.61 and a two-hundred day moving average of $1.32. Werewolf Therapeutics, Inc. has a 12-month low of $0.60 and a 12-month high of $2.39. The firm has a market cap of $54.61 million, a P/E ratio of -0.69 and a beta of 0.72. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.87 and a quick ratio of 5.30.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Tuesday, November 4th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. As a group, sell-side analysts expect that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Analysts Set New Price Targets

HOWL has been the subject of a number of analyst reports. Bank of America dropped their price objective on Werewolf Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Monday, August 25th. Zacks Research raised shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 16th. JMP Securities decreased their price objective on shares of Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a research note on Wednesday, October 8th. Finally, Citigroup reissued a “buy” rating on shares of Werewolf Therapeutics in a research note on Monday, August 25th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $8.00.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Quadrature Capital Ltd purchased a new position in shares of Werewolf Therapeutics in the 2nd quarter valued at approximately $28,000. Vontobel Holding Ltd. bought a new position in Werewolf Therapeutics in the first quarter worth $34,000. Qube Research & Technologies Ltd purchased a new position in Werewolf Therapeutics during the second quarter valued at $48,000. Nuveen LLC purchased a new position in Werewolf Therapeutics during the first quarter valued at $71,000. Finally, AQR Capital Management LLC bought a new stake in shares of Werewolf Therapeutics during the 1st quarter valued at $79,000. Hedge funds and other institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.